Results 71 to 80 of about 2,131 (192)

Functional and proteomic analysis of a full thickness filaggrin-deficient skin organoid model [PDF]

, 2019
Background: Atopic eczema is an itchy inflammatory disorder characterised by skin barrier dysfunction. Loss-of-function mutations in the gene encoding filaggrin (FLG) are a major risk factor, but the mechanisms by which filaggrin haploinsufficiency leads
A Fabregat, A Naeem, A Sandilands, A Sandilands, B Kim, C Cole, C Cole, C Finan, C Flohr, C Hausmann, C He, C Lefèvre, C Palmer, D Szklarczyk, D Tobin, E Hoste, E Leclerc, E Rodriguez, E van den Bogaard, F Smith, G Denecker, G McIlroy, H Alexander, H Baurecht, H Han, H Niehues, J Bergboer, J Folch, J Rheinwald, J Silverberg, J Timmerman, K Purdie, K Vávrová, L Paternoster, M Elias, M Elias, M Ferreira, M Kamsteeg, M Kretz, M Visser, N Markova, N Novak, P Arkwright, P Di Meglio, P Gao, R Gruber, R Gruber, R Mateu, S Brown, S Brown, S Brown, S Brown, S Brown, S Brown, S Brown, S Brown, S Brown, S Johansson, S Smith, S Weidinger, T Elango, T Gil, T Matsui, V Rothhammer, V van Drongelen, W Damsky, W Nirunsuksiri, Y Dou, Y Lee, Y Perez-Riverol, Z Xie, Z Zhu   +71 more
core   +3 more sources

Infections in Dupilumab Clinical Trials in Atopic Dermatitis : A Comprehensive Pooled Analysis [PDF]

, 2019
Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus ...
Akinlade, B., Ardeleanu, M., Beck, L.A., Bieber, T., Chen, Z., de Bruin-Weller, Marjolein, Deleuran, M., Eichenfield, L.F., Ferrándiz, Carlos, Fölster-Holst, R., Graham, N.M.H., Pirozzi, G., Silverberg, J.I., Simpson, E.L., Thaçi, Diamant, Universitat Autònoma de Barcelona, Yancopoulos, G.D.   +16 more
core   +1 more source

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 12, Page 2056-2068, December 2025.
This cohort study of 1793 atopic dermatitis patients (aged ≥ 12) found higher infection rates with Janus kinase inhibitor treatment compared to biologic treatment, particularly for herpes infections, with a history of viral or fungal skin infection as a risk factor associated with infection.
Lian F. van der Gang, Keneshka Atash, Nicolaas P. A. Zuithoff, Inge Haeck, Celeste M. Boesjes, Octavian I. Bacoş‐Cosma, Laura Loman, Marijke Kamsteeg, Simone Stadhouders‐Keet, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Klaziena Politiek, Antoni Gostynksi, Lisette Berntsen‐Zandbergen, Wianda A. Christoffers, Annebeth Flinterman, Wouter R. H. Touwslager, Berit Velstra, Shiarra M. Stewart, Francine C. van Erp, Marlies de Graaf, Marie‐Louise A. Schuttelaar, Marjolein S. de Bruin‐Weller   +22 more
wiley   +1 more source

Drowning and three-wheel strollers [PDF]

, 2007
©The Medical Journal of Australia 2007 The document attached has been archived with permission from the editor of the Medical Journal of Australia (26 April 2007).
Byard, R., Matthews, N.
core   +1 more source

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, Volume 599, Issue 22, Page 3208-3243, November 2025.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

Psychosocial Determinants and Atopic Dermatitis Outcomes: A Cross‐Sectional Study From an Australian Paediatric Centre

Australasian Journal of Dermatology, Volume 66, Issue 6, Page e346-e354, September 2025.
ABSTRACT Background Atopic dermatitis (AD) significantly impacts quality of life, with well‐documented physical and psychological consequences. While disease burden is well characterised, the influence of psychosocial determinants on AD outcomes remains underexplored. This study examines these factors in an Australian paediatric population.
Ashling Courtney, Anousha Yazdabadi, Emily Schembri, Adrian J. Lowe, Crystal Williams, John C. Su   +5 more
wiley   +1 more source

Microbiology of infected eczema herpeticum [PDF]

Journal of the American Academy of Dermatology, 1998
Secondary bacterial infection in eczema herpeticum (EH) is common. Staphylococcus aureus alone or mixed with group A β-hemolytic streptococci (GABHS) and Pseudomonas aeruginosa were found to be the major isolates from patients with secondary bacterial infection in EH.1 Previous studies of the microbiology of secondary bacterial infection of EH employed
I, Brook, E H, Frazier, J K, Yeager
openaire   +2 more sources

Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Clinical &Experimental Allergy, Volume 55, Issue 9, Page 755-772, September 2025.
This systematic review and meta‐analysis of 50 cohort studies summarises the real‐world effectiveness and safety of systemic JAK inhibitors for the treatment of moderate to severe atopic dermatitis. ABSTRACT Objective The aim of this study is to evaluate the effectiveness and safety of JAK inhibitors in patients with moderate to severe atopic ...
Yunha Kim, Gayeong Seo, Jacob J. E. Koopman, Jeong Yee   +3 more
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 9, Page 1537-1566, September 2025.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Kaposi′s varicelliform eruption: A case series

Indian Dermatology Online Journal, 2015
Kaposi's varicelliform eruption is a rare and potentially fatal viral infection caused mainly by reactivation of herpes simplex virus. It concomitantly occurs with pre-existing skin conditions, mostly atopic dermatitis, so it is predominately found in ...
Bruno Ferrari, Vanina Taliercio, Paula Luna, María Eugenia Abad, Margarita Larralde   +4 more
doaj   +1 more source